JPM vs PFE: Which Is the Better Buy?
Side-by-side comparison of JPMorgan Chase & Co. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-14.
JPMorgan Chase & Co. · Financial Services
$334.53
+45.0% upside to fair value
Grade B
High Quality
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
JPM has more upside to fair value
(+45.0%).
JPM trades at a lower forward P/E
(14.3x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
JPM |
PFE |
| Current Price |
$334.53 |
$25.22 |
| Fair Value Estimate |
$485.07 |
$25.92 |
| Upside to Fair Value |
+45.0%
|
+2.8%
|
| Market Cap |
$896.4B |
$143.7B |
| Forward P/E |
14.3x
|
19.2x
|
| EV / EBITDA |
12.4x
|
12.3x
|
| Price / Sales |
5.4x
|
2.3x
|
| Price / FCF |
6.4x
|
15.2x
|
| Revenue Growth YoY |
-168.4%
|
+5.4%
|
| Gross Margin |
78.6%
|
69.3%
|
| Operating Margin |
33.7%
|
23.4%
|
| Return on Equity |
17.8%
|
8.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
15.72%
|
6.6%
|
| Analyst Consensus |
Buy
|
Hold
|
Investment Thesis
JPMorgan Chase & Co. operates as a leading diversified bank within the financial services sector, demonstrating a high-quality business model characterized by a strong return on equity of 17.8% and robust profitability margins including a net margin of 38.9%. Despite a significant revenue decline of 168.4% year-over-year in the most recent quarter, earnings grew by 41.2%, reflecting operational e…
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
JPM |
PFE |
| Zone Low |
$363.80 |
$19.44 |
| Zone High |
$412.31 |
$22.03 |
| In Buy Zone? |
Yes
|
No
|